OCUGEN, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
OCUGEN, INC. (OCGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-22.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2019-03-22
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2018-09-30 was 0.00%.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2018-06-30 was 0.00%.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2018-03-31 was 0.00%.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2017-09-30 was 0.00%.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2018 was 0.00%.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2017 was 0.00%.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2016 was 0.00%.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2015 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2018-12-31 | 0.00% 10-K · filed 2019-03-22 | |||
| 2018-09-30 | 0.00% 10-Q · filed 2018-11-08 | 0.00% 10-Q · filed 2018-11-08 | ||
| 2018-06-30 | 0.00% 10-Q · filed 2018-08-09 | 0.00% 10-Q · filed 2018-08-09 | ||
| 2018-03-31 | 0.00% 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | 0.00% 10-K · filed 2019-03-22 | |||
| 2017-09-30 | 0.00% 10-Q · filed 2018-11-08 | 0.00% 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | 0.00% 10-Q · filed 2018-08-09 | 0.00% 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | 0.00% 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | 0.00% 10-K · filed 2018-03-15 | |||
| 2016-09-30 | 0.00% 10-Q · filed 2017-11-09 | 0.00% 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | 0.00% 10-Q · filed 2017-08-10 | 0.00% 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | 0.00% 10-Q · filed 2017-05-11 | |||
| 2015-12-31 | 0.00% 10-K · filed 2017-03-16 | |||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-10 | 0.00% 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | 0.00% 10-Q · filed 2016-08-11 | 0.00% 10-Q · filed 2016-08-11 | ||
| 2015-03-31 | 0.00% 10-Q · filed 2016-05-12 | |||
| 2014-12-31 | 0.00% 10-K · filed 2016-03-10 | |||
| 2014-09-30 | 0.00% 10-Q · filed 2015-11-12 | 0.00% 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | 0.00% 10-Q · filed 2015-08-12 | 0.00% 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | 0.00% 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |